Clinical Data Novo, Lilly trade oral GLP-1 data readouts at ECO PharmaphorumNovo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaphorum Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Isomorphic Labs receives $2.1bn for AI drug developmentNext: UAE approves AstraZeneca’s Baxfendy for hypertension Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
